An multicenter open-label long-term continuous administration study to investigate the safety and tolerability of lucerastat in Japanese Fabry disease patients
Phase 3
- Conditions
- Fabry disease
- Registration Number
- JPRN-jRCT2080224890
- Lead Sponsor
- Idorsia Pharmaceuticals Japan Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- other
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Patients who complete the preceding study and continue its eligibility
Exclusion Criteria
Patients with a risk of worsening of clinical symptoms due to an organ lesion during the study period at the discretion of the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method